Organogenesis - Revision history

WikiModEn2: /* Apligraph Oral */ Update URL.

2022-11-04T23:10:23Z

Apligraph Oral: Update URL.

← Older revision		Revision as of 23:10, 4 November 2022
Line 40:		Line 40:
	\|date=2011-11-17		\|date=2011-11-17
	\|title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript		\|title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript
	\|url=~~http~~://www.fda.gov/~~downloads~~/~~AdvisoryCommittees~~/~~CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdf~~		\|url=https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-september-2-3-2021-meeting-announcement
	\|publisher=		\|publisher=
	\|accessdate=~~2011~~-12-20		\|accessdate=2021-09-02
	}}</ref>		}}</ref>

WikiModEn2: /* Apligraph Oral */ Add categories; Wikify.

2022-11-04T23:06:45Z

Apligraph Oral: Add categories; Wikify.

← Older revision		Revision as of 23:06, 4 November 2022
Line 35:		Line 35:

	== Apligraph Oral ==		== Apligraph Oral ==
	Organogenesis is presently seeking [[FDA]] approval for Apligraph Oral, a foreskin-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref>{{REFweb		Organogenesis is presently seeking [[FDA]] approval for Apligraph Oral, a [[foreskin]]-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref>{{REFweb
	\|last=		\|last=
	\|first=		\|first=
Line 48:		Line 48:

	[[Category:Company]]		[[Category:Company]]
			[[Category:Financial gain]]
			[[Category:Foreskin product]]

	[[Category:From CircLeaks]]		[[Category:From CircLeaks]]

WikiModEn2: /* Call for increase of foreskin harvesting */ Wikify.

2022-07-07T19:51:45Z

Call for increase of foreskin harvesting: Wikify.

← Older revision		Revision as of 19:51, 7 July 2022
Line 23:		Line 23:
	{{Citation		{{Citation
	\|Title=We Must Be Able To Obtain Adequate Sources Of Supply		\|Title=We Must Be Able To Obtain Adequate Sources Of Supply
	\|Text=We manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant foreskin, they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the [[HIV]] or "[[AIDS]]" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products.		\|Text=We manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant [[foreskin]], they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the [[HIV]] or "[[AIDS]]" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products.
	\|Author=		\|Author=
	\|Source=Organogensis		\|Source=Organogensis

WikiAdmin: wikify skin

2021-12-27T15:11:01Z

wikify skin

← Older revision		Revision as of 15:11, 27 December 2021
Line 9:		Line 9:
	\|url=http://www.organogenesis.com/about_us/headquarters.html		\|url=http://www.organogenesis.com/about_us/headquarters.html
	\|accessdate=2011-03-06		\|accessdate=2011-03-06
	}}</ref> They profit from [[Apligraf]], which is a synthetic skin created from harvested foreskins.<ref name='Organogenesis 2011'>{{REFweb		}}</ref> They profit from [[Apligraf]], which is a synthetic [[skin]] created from harvested foreskins.<ref name='Organogenesis 2011'>{{REFweb
	\|quote=Human keratinocytes and fibroblasts are derived from neonatal foreskins.		\|quote=Human keratinocytes and fibroblasts are derived from neonatal foreskins.
	\|last=		\|last=

WikiAdmin: wikify AIDS

2021-12-01T09:41:52Z

wikify AIDS

← Older revision		Revision as of 09:41, 1 December 2021
Line 23:		Line 23:
	{{Citation		{{Citation
	\|Title=We Must Be Able To Obtain Adequate Sources Of Supply		\|Title=We Must Be Able To Obtain Adequate Sources Of Supply
	\|Text=We manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant foreskin, they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the [[HIV]] or "AIDS" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products.		\|Text=We manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant foreskin, they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the [[HIV]] or "[[AIDS]]" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products.
	\|Author=		\|Author=
	\|Source=Organogensis		\|Source=Organogensis

WikiAdmin: wikify HIV

2021-11-24T14:56:45Z

wikify HIV

← Older revision		Revision as of 14:56, 24 November 2021
Line 23:		Line 23:
	{{Citation		{{Citation
	\|Title=We Must Be Able To Obtain Adequate Sources Of Supply		\|Title=We Must Be Able To Obtain Adequate Sources Of Supply
	\|Text=We manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant foreskin, they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the HIV or "AIDS" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products.		\|Text=We manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant foreskin, they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the [[HIV]] or "AIDS" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products.
	\|Author=		\|Author=
	\|Source=Organogensis		\|Source=Organogensis

WikiAdmin: adjusted category

2021-11-09T19:09:16Z

adjusted category

← Older revision		Revision as of 19:09, 9 November 2021
Line 47:		Line 47:
	{{REF}}		{{REF}}

	[[Category:~~Organizations~~]]		[[Category:Company]]

	[[Category:From CircLeaks]]		[[Category:From CircLeaks]]

WikiAdmin: add interlanguage link

2019-12-01T14:04:36Z

add interlanguage link

← Older revision		Revision as of 14:04, 1 December 2019
Line 51:		Line 51:
	[[Category:From CircLeaks]]		[[Category:From CircLeaks]]
	[[Category:From IntactWiki]]		[[Category:From IntactWiki]]

			[[de:{{FULLPAGENAME}}]]

WikiAdmin: Fixed date format error.

2019-11-02T10:35:09Z

Fixed date format error.

← Older revision		Revision as of 10:35, 2 November 2019
Line 38:		Line 38:
	\|last=		\|last=
	\|first=		\|first=
	\|date=~~November~~ 2011		\|date=2011-11-17
	\|title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript		\|title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript
	\|url=http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdf		\|url=http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdf

WikiAdmin: reformatted REFweb

2019-10-04T08:31:16Z

reformatted REFweb

← Older revision		Revision as of 08:31, 4 October 2019
Line 1:		Line 1:
	[[Image:Organogenesis_logo.jpg\|right\|thumb\|]]		[[Image:Organogenesis_logo.jpg\|right\|thumb\|]]
	'''Organogenesis''' is a corporation based in Canton, MA.<ref name='Organogenesis 2010'>{{REFweb		'''Organogenesis''' is a corporation based in Canton, MA.<ref name='Organogenesis 2010'>{{REFweb
	\| quote=The corporate headquarters and manufacturing facility are located in Canton, Massachusetts.		\|quote=The corporate headquarters and manufacturing facility are located in Canton, Massachusetts.
	\| last=		\|last=
	\| first=		\|first=
	\| publisher=Organogenesis		\|publisher=Organogenesis
	~~\| work=~~		\|date=2010
	\| date=2010		\|title=Headquarters
	\| title=Headquarters		\|url=http://www.organogenesis.com/about_us/headquarters.html
	\| url=http://www.organogenesis.com/about_us/headquarters.html		\|accessdate=2011-03-06
	\| accessdate=2011-03-06
	}}</ref> They profit from [[Apligraf]], which is a synthetic skin created from harvested foreskins.<ref name='Organogenesis 2011'>{{REFweb		}}</ref> They profit from [[Apligraf]], which is a synthetic skin created from harvested foreskins.<ref name='Organogenesis 2011'>{{REFweb
	\| quote=Human keratinocytes and fibroblasts are derived from neonatal foreskins.		\|quote=Human keratinocytes and fibroblasts are derived from neonatal foreskins.
	\| last=		\|last=
	\| first=		\|first=
	\| publisher=Organogenesis		\|publisher=Organogenesis
	~~\| work=~~		\|date=2011
	\| date=2011		\|title=Apligraf: How Is It Made?
	\| title=Apligraf: How Is It Made?		\|url=http://www.apligraf.com/professional/what_is_apligraf/how_is_it_made/
	\| url=http://www.apligraf.com/professional/what_is_apligraf/how_is_it_made/		\|accessdate=2011-03-06
	\| accessdate=2011-03-06
	}}</ref> Novartis Pharmaceuticals Corp. has global marketing rights to Apligraf.		}}</ref> Novartis Pharmaceuticals Corp. has global marketing rights to Apligraf.

	== Call for increase of foreskin harvesting ==		== Call for increase of foreskin harvesting ==
	{{Citation		{{Citation
	\| Title=We Must Be Able To Obtain Adequate Sources Of Supply		\|Title=We Must Be Able To Obtain Adequate Sources Of Supply
	\| Text=e manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant foreskin, they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the HIV or "AIDS" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products.		\|Text=We manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant foreskin, they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the HIV or "AIDS" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products.
	\| Author=		\|Author=
	\| Source=Organogensis		\|Source=Organogensis
	\| lang=		\|lang=
	\| before=		\|before=
	\| after=		\|after=
	\| Transcription=		\|Transcription=
	\| Translation=		\|Translation=
	\| ref=<ref>[http://sec.edgar-online.com/organogenesis-inc/10-k-annual-report/2001/04/02/Section2.aspx Organogensis, 2001 Annual Report (Delaware: Organogenesis, 2001), p.8.]</ref>		\|ref=<ref>[http://sec.edgar-online.com/organogenesis-inc/10-k-annual-report/2001/04/02/Section2.aspx Organogensis, 2001 Annual Report (Delaware: Organogenesis, 2001), p.8.]</ref>
	}}		}}

	== Apligraph Oral ==		== Apligraph Oral ==
	Organogenesis is presently seeking [[FDA]] approval for Apligraph Oral, a foreskin-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref>{{REFweb		Organogenesis is presently seeking [[FDA]] approval for Apligraph Oral, a foreskin-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref>{{REFweb
	\| last=		\|last=
	\| first=		\|first=
	\| date=November 2011		\|date=November 2011
	\| title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript		\|title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript
	\| url=http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdf		\|url=http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdf
	\| publisher=		\|publisher=
	\| accessdate=2011-12-20		\|accessdate=2011-12-20
	}}</ref>		}}</ref>